News Column

ARIAD Announces Proposed $175 Million Offering of Convertible Senior Notes Due 2019

June 23, 2014



By a News Reporter-Staff News Editor at Clinical Trials Week -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced its intention to offer, subject to market and other conditions, $175 million aggregate principal amount of convertible senior notes due 2019 (the "Notes") in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the "Act"). ARIAD also intends to grant the initial purchasers of the Notes an option, exercisable for 30 days, to purchase up to an additional $50 million aggregate principal amount of the Notes on the same terms and conditions (see also Pharmaceutical Companies).

The Notes will be senior unsecured obligations of ARIAD, and interest will be payable semi-annually. The Notes will be convertible by the holders beginning December 15, 2018, or earlier upon specified events, and upon conversion, the holders will receive, at ARIAD's option, shares of ARIAD's common stock, cash or a combination of shares and cash. The interest rate, initial conversion rate and other terms of the Notes will be determined by negotiations between ARIAD and the initial purchasers.

In connection with the pricing of the Notes, ARIAD expects to enter into a convertible note hedge transaction with an affiliate of one of the initial purchasers (the "option counterparty"). The convertible note hedge transaction is expected generally to reduce the potential dilution to ARIAD's common stock upon any conversion of Notes and/or offset any cash payments ARIAD may be required to make in excess of the principal amount of converted Notes, in each case, in the event that the market price per share of ARIAD's common stock, as measured under the terms of the convertible note hedge transaction, is greater than the strike price of the convertible note hedge transaction. ARIAD also expects to enter into a warrant transaction with the option counterparty. The warrant transaction could separately have a dilutive effect to the extent that the market value per share of ARIAD's common stock as measured over the applicable valuation period at the maturity of the warrants exceeds the applicable strike price of the warrants.

ARIAD expects that in connection with establishing its initial hedge of the convertible note hedge and warrant transactions, the option counterparty or an affiliate thereof expects to enter into various derivative transactions with respect to ARIAD's common stock concurrently with or shortly after the pricing of the Notes. This activity could increase (or reduce the size of any decrease in) the market price of ARIAD's common stock or the Notes at that time. In addition, ARIAD expects that the option counterparty or an affiliate thereof may modify its hedge positions from time to time by entering into or unwinding various derivatives with respect to ARIAD's common stock or other ARIAD securities in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and are likely to do so during any observation period related to a conversion of the Notes). This activity could also cause or avoid an increase or a decrease in the market price of ARIAD's common stock or the Notes, which could affect the ability of Note holders to convert the Notes and, to the extent the activity occurs during any observation period related to a conversion of the Notes, it could affect the amount and value of the consideration that Note holders will receive upon conversion of the Notes.

ARIAD intends to use a portion of the net proceeds of the offering to pay the cost of the convertible note hedge transaction (after such cost is partially offset by the proceeds from the warrant transaction). ARIAD intends to use the remainder of the net proceeds of the offering for its operations, including, but not limited to sales, marketing, manufacturing and distribution of IclusigŪ (ponatinib); global development of its other product candidates, including clinical trials, product and process development, manufacturing and other activities; discovery research efforts to add to its pipeline of product candidates; and for other general corporate purposes, including, but not limited to repayment or refinancing of indebtedness or other corporate borrowings, capital expenditures and possible acquisitions.

The Notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Act. Neither the Notes nor the shares of ARIAD's common stock issuable upon conversion of the Notes, if any, have been registered under the Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements.

Keywords for this news article include: ARIAD Pharmaceuticals Inc., Pharmaceutical Companies, Biotechnology Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters